{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:23:24Z","timestamp":1706574204317},"reference-count":4,"publisher":"American Society of Consultant Pharmacists","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:p><jats:bold>Objective<\/jats:bold> The purpose of this study was to determine the clinical impact of a specialized pharmacist-led medication assessment on the incidence of dopamine antagonists administered for patients with Parkinson\u2019s disease after deep brain stimulation (DBS).  <jats:bold>Methods<\/jats:bold>\n This was a single-center, Institutional Review Board-approved, two-phase study with pre- and post-implementation cohorts of patients who were 18 years of age or older who underwent DBS for treatment of Parkinson\u2019s disease. The primary endpoint was the incidence of dopamine antagonists\n administered after DBS procedure. Secondary endpoints included the incidence of dopamine antagonists ordered; restarting home Parkinson\u2019s disease regimen; rate of tardive dyskinesia; length of hospital stay; and incidence of sitters, restraints, and medications administered for acute\n agitation. Statistical analysis included Fisher\u2019s exact test for categorical data, unpaired <jats:italic>t<\/jats:italic>-test for continuous data, and descriptive statistics for all other data.  <jats:bold>Results<\/jats:bold> The incidence of dopamine antagonists administered was 1 (1.2%) versus 1 (25%) for\n the pre- and post-implementation groups, respectively (<jats:italic>P<\/jats:italic> = 0.09). Restarting of home Parkinson\u2019s disease regimen was 30 (36.1%) versus 4 (100%); <jats:italic>P<\/jats:italic> = 0.021. The average length of stay was 1.9 days versus 1.3 days. Incidence of sitters was 1 (1.2%) versus 0 (0%), and incidence\n of restraints was 0 (0%) versus 0 (0%). Incidence of acute agitation medications administered was 9 (10.8%) versus 0 (0%). The secondary endpoints were not significant except for the restarting of home medication regimen.  <jats:bold>Conclusion<\/jats:bold> The specialized pharmacist-led medication\n review service identified a single incident of inappropriate medications administered for Parkinson\u2019s disease patients status post DBS. However, it did significantly increase the incidence of the restart of Parkinson\u2019s disease home regimen.<\/jats:p>","DOI":"10.4140\/tcp.n.2024.87","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T12:24:08Z","timestamp":1706531048000},"page":"87-92","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of Pharmacist-Led Medication Review Service for Parkinson\u2019s Disease Patients Admitted for Deep Brain Stimulation"],"prefix":"10.4140","volume":"39","author":[{"given":"Ugene","family":"Sano","sequence":"first","affiliation":[{"name":"Cooperman Barnabas Medical Center, Livingston, New Jersey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Jacisin","sequence":"additional","affiliation":[{"name":"Cooperman Barnabas Medical Center, Livingston, New Jersey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Bente","sequence":"additional","affiliation":[{"name":"Cooperman Barnabas Medical Center, Livingston, New Jersey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/pgmj.2009.080432","article-title":"Medication management in people with Parkinson\u2019s disease during surgical admissions.","volume":"86","year":"2010","journal-title":"Postgrad Med J."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/157488512803988067","article-title":"Inappropriate antidopaminergic drug use in Parkinson\u2019s disease inpatients.","volume":"7","year":"2012","journal-title":"Curr Drug Ther."},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"e0267969","DOI":"10.1371\/journal.pone.0267969","article-title":"Identifying rates and risk factors for medication errors during hospitalization in the Australian Parkinson\u2019s disease population: a 3-year, multi-center study.","volume":"17","year":"2022","journal-title":"PLoS One."},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2125.2009.03424.x","article-title":"Medication errors: the importance of an accurate drug history.","volume":"67","year":"2009","journal-title":"Br J Clin Pharmacol."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2024\/00000039\/00000002\/art00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T12:24:34Z","timestamp":1706531074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2024.87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":4,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"alternative-id":["2639-9636(20240201)39:2L.87;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2024.87","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}